China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval to introduce Elahere (mirvetuximab soravtansine), an antibody drug conjugate (ADC) targeting folate receptor α (FRα), at Ruijin Hospital’s Hainan branch. The treatment is indicated for FRα positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer in adult patients who have previously received 1-3 systemic treatments.
Huadong’s Acquisition of Mirvetuximab Soravtansine Rights
Huadong acquired the Greater China development and commercial rights to mirvetuximab soravtansine from ImmunoGen Inc. in an October 2020 deal valued at up to USD 305 million. This strategic acquisition has positioned Huadong to bring this innovative treatment to patients in need within the region.Immunogen
-Fineline Info & TechPriority Review Status and Implications for Cancer Treatment
The ADC was awarded priority review status in China in July 2023, underscoring the urgency and importance of expanding treatment options for patients with FRα positive cancers. The approval of Elahere marks a significant advancement in the treatment landscape for platinum-resistant epithelial ovarian cancer and related diseases, offering a new therapeutic option for patients who have limited alternatives after multiple systemic treatments.-Fineline Info & Tech
